Douglas Cole, M.D.

Doug joined Flagship in 2001 where he focuses on Life Science investments. He came to Flagship with significant industrial experience and a strong academic background. He obtained post-graduate training in medicine at the Johns Hopkins Hospital in Baltimore, MD and in neurology the Massachusetts General Hospital in Boston, MA. In 1992, Doug was appointed Instructor in Neurology at Harvard Medical School and an Assistant in Neurology at the Massachusetts General Hospital. He established a research program investigating the mechanistic basis of neuronal signaling events and plasticity in neuro-psychiatric disorders with the support of the NIH and several non-profit research foundations. Doug holds an AB magna cum laude with High Distinction in English from Dartmouth College, where he was a Senior Fellow and a member of Phi Beta Kappa, and an MD from the University of Pennsylvania School of Medicine, where he was a member of Alpha Omega Alpha.

In 1996, Doug joined Cytotherapeutics, in Providence, RI. As Medical Director he oversaw various research and clinical activities related to the company’s cell-based therapeutic technologies. In 1997, he was appointed Program Executive at Vertex Pharmaceuticals, Inc., in Cambridge, MA, where he led a multidisciplinary program that conducted preclinical development through Phase II studies in tissue protection and repair, oversaw an international research collaboration, and was responsible for identifying strategic market and technology opportunities in multiple arenas.

At Flagship, Doug has led investments in CombinatoRx (NASDAQ: CRXX), Alinea Pharmaceuticals, Tetraphase, Alvine Pharmaceuticals, and Concert Pharmaceuticals. He co-founded Ensemble Discovery with Noubar Afeyan and Professor David Liu of Harvard University, and he served as CEO of the company in its initial stages. He currently serves on the Boards of Directors of Ensemble Discovery, Tetraphase, Concert Pharmaceuticals, AVEO Pharmaceuticals, and CGI Pharmaceuticals, and is an Observer on the Board of Directors of Alinea, and Alvine. He formerly served on the Board of Directors of CombinatoRx and Morphotek. He is a member of the Scientific Advisory Board of the Spinal Muscular Atrophy Foundation and the Genetics Advisory Council of the Harvard-Partners Center for Genetics and Genomics, and serves on the Board of Directors of the Birch Rock Camp in Waterford, ME.